secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2022-05-17T23:59:59+00:00
Accession:  0001607062-22-000359
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma issues 100M shares to settle debt; subsidiary gets NR2F6 patent
-------------------------------------------------------------------------------

- Issued 100M common shares to Coventry Enterprises LLC to satisfy $334,800 of convertible debt; note balance now $648,001.
- KCL Therapeutics subsidiary awarded U.S. Patent No. 11,324,719 for small molecule NR2F6 agonists/antagonists.
- Shares issued under Section 4(a)(2) exemption without underwriters or general solicitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706222000359/0001607062-22-000359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706222000359/rgbp051622form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-22-000359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer